Showing 1489 results
-
Press release /Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between…
-
Press release /Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months…
-
Press release /CHMP positive opinion for EU approval of Tafinlar and Mekinist combination in BRAF V600 mutation-positive melanoma, the most aggressive type of skin cancer FDA grants priority review for…
-
Story /Pneumonia causes around 2 million child deaths per year globally and the burden is especially heavy in a country like Bangladesh, where a third of the population is aged 14 or below.
-
Ad hoc release /Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by…
-
Story /Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.
-
Story /Jordan, a melanoma survivor, shares her experience with melanoma, BRAF mutation testing and the importance of patient empowerment.
-
Story /Yan Zhao talks about how her team in China responded to an emerging public health crisis.